Beijing TongRenTang Co., Ltd. Class A

Beijing TongRenTang Co., Ltd. Class A

SSSE:600085
24.12
CNY
-0.01
(-0.04%)
0.80EPS
37.09P/E
32.56BMarket Cap
Mar 30Next Earn
Beijing TongRenTang Co., Ltd. Class A
SSE:600085
(Shanghai Stock Exchange)

Recent

price

24.12

P/E

ratio

37.09

div

yld

1.99%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.79
4.69
5.78
6.68
7.38
8.03
8.81
9.76
10.36
9.69
9.35
10.65
11.21
13.03
13.56
12.58
10.95
Revenue per Share
0.26
0.34
0.44
0.5
0.58
0.64
0.68
0.74
0.83
0.72
0.75
0.89
1.04
1.22
1.11
0.87
0.64
Basic EPS, GAAP
0.35
0.09
0.45
0.19
0.1
0.22
0.25
0.51
0.96
1.32
0.75
2.15
2.02
1.13
0.18
1.7
- -
Free Cash Flow per Basic Share
0.11
0.15
0.16
0.27
0.22
0.24
0.24
0.27
0.34
0.79
0.31
0.33
0.32
0.35
1
0.51
0.48
Dividend per Share
2.49
2.67
3.06
3.83
4.21
5.19
5.68
6.14
6.75
6.73
7.17
7.75
8.61
9.52
9.62
9.96
10.02
Book Value per Share
2.42
2.52
2.83
3.6
3.96
4.91
5.4
5.85
6.44
6.38
6.67
7.19
8.03
8.94
9.02
9.36
9.44
Tangible Book Value per Share
1,304
1,304
1,302
1,304
1,312
1,357
1,372
1,371
1,372
1,371
1,372
1,371
1,371
1,371
1,371
1,372
1,371
Basic Weighted Avg Shares
4,943
6,108
7,517
8,715
9,686
10,897
12,091
13,376
14,209
13,277
12,826
14,603
15,372
17,861
18,597
17,256
15,007
Sales/Revenue/Turnover
13.59
14.24
15.17
14.8
15.4
16.44
16.1
16.61
15.75
15.31
16.42
17.68
18.18
17.33
14.98
12.1
9.09
Operating Margin (%)
103
101
104
111
132
152
164
183
204
249
343
827
886
915
971
1,051
- -
Depreciation Expense
340
438
570
656
764
875
933
1,017
1,134
985
1,031
1,227
1,427
1,669
1,526
1,189
878
Net Income, GAAP
17.46
18.34
18.38
17.68
17.64
17.63
18.5
18.62
19.16
20.6
18.49
18.76
18.88
16.15
18.72
19.42
22.29
Effective Tax Rate (%)
6.89
7.17
7.58
7.53
7.88
8.03
7.72
7.61
7.98
7.42
8.04
8.4
9.29
9.34
8.21
6.89
5.85
Profit Margin (%)
3,324
3,530
5,184
7,018
7,299
8,089
9,531
10,220
11,170
11,219
10,474
11,871
14,224
16,199
16,098
16,884
16,609
Working Capital
- -
16
1,026
947
955
10
925
928
915
1,231
1,708
1,881
2,083
2,495
2,504
2,541
1,996
LT Debt
4,428
4,811
5,607
7,837
8,646
10,881
12,078
13,168
14,529
14,660
15,546
16,673
18,464
20,257
20,901
21,378
21,248
Total Equity
11.66
13.5
14.4
13.02
13
13.64
12.36
12.4
12.06
9.68
9.27
9.74
10.63
11.5
9.36
6.51
4.4
Return on Invested Capital (%)
4.04
4.76
4.59
3.34
3.07
2.79
2.59
2.28
3.07
2.78
2.79
3.44
3.59
3.76
3.63
3.37
2.96
Return on Capital (%)
10.81
13.03
15.29
14.58
14.5
13.85
12.51
12.55
12.83
10.66
10.82
11.99
12.72
13.42
11.63
8.86
6.46
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
939
1,244
1,134
LT Borrowings
1,409
1,109
1,005
LT Finance Leases
1,183
1,070
991
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,371
1,371
1,371
Market Capitalization
38,099
31,695
32,559

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
23,829
22,990
22,497
Cash, Cash Equivalents & STI
11,517
11,026
10,873
Accounts Receivable, Net
1,889
1,536
1,361
Inventories
9,622
9,393
9,432
Total Current Liabilities
6,325
6,434
5,887
Payables & Accruals
- -
- -
- -
ST Debt
939
1,244
1,134
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.05%
6.63%
2.28%
Free Cash Flow
112.47%
184.23%
867.38%
Net Income, GAAP
4.03%
4.32%
-22.07%
Sales/Revenue/Turnover
5.01%
6.45%
-7.21%
Total Cash Common Dividend
26.03%
29.59%
-49.38%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,267
4,496
4,057
4,778
18,597
2025
5,276
4,493
- -
3,948
17,256
2026
4,664
3,715
2,680
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
0.32
0.24
0.13
1.11
2025
0.43
0.26
- -
0.01
0.87
2026
0.34
0.19
0.1
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.51
- -
0.48
1
2025
0.01
0.51
- -
-0.03
0.51
2026
0.03
0.47
0.01
- -
- -
Business
Beijing Tongrentang Co., Ltd. (600085.SS) engages in the research, development, production, distribution, and sale of traditional Chinese patent medicines and related healthcare products primarily in China and internationally. The company offers a wide range of dosage forms including pills, powders, wine preparations, capsules, and oral liquids targeting therapeutic areas such as cardiovascular conditions, gynecology, heat-clearing remedies, respiratory system disorders, nourishing and calming treatments, digestive system issues, pediatrics, wind-dispelling and dampness-removing formulas, orthopedics, five senses ailments, dermatology, psychological health, and food and wine products; it also provides complementary services like traditional Chinese medicine consultations, acupuncture, Tuina massage, Qigong exercise, dietary therapies, and herbal medicine brewing through its clinics and retail network. Founded in 1669 during the Qing Dynasty and headquartered in Beijing, the company operates manufacturing facilities and over 140 branches across 29 countries and regions, with a strong presence in Chinese-speaking markets and expanding global outreach via its Hong Kong-based group established in 2004. In recent developments, Beijing Tongrentang Technology, a related entity, formed a strategic partnership with Nisun International in October 2024 to supply traditional Chinese medicine materials, enhancing supply chain diversification; additionally, in January 2024, the company transferred equity in certain healthcare assets to Beijing Tong Ren Tang Healthcare Investment Co., Ltd., supporting ongoing mergers and acquisitions in the medical sector, while the group pursues further hospital acquisitions targeting five by 2028.